PD-L1 immunohistochemistry
A staining test to assess PD-L1 expression and its score.
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
Purpose of the test
- Generates TPS or CPS scores according to tumor type.
- Helps interpret the relevance of immunotherapy.
Informs decisions
- Interpretation of immunotherapy categories.
- Compliance criteria for some clinical trials.
How the test is done
PD-L1 antibody staining of tumor tissue is then calculated according to the applicable scoring rules.
- Sample type
- Block tumor tissue
- Estimated result time
- Generally several working days.
Limitations
- Scores from different types of cancer cannot be directly compared.
- Different platforms and antibodies result in different reporting.
- The time of sampling affects the relevance of the results.
Related
Cancer types
Markers tested
Not displayed
TanyaKanker does not display test-cost estimates. Ask the laboratory or facility providing the test for cost details directly.
Sources
- NCI Dictionary of Cancer Terms(lembaga)
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
To check
- Stomach Cancer
Cancer type
Reason: Memerlukan pemeriksaan
- Lung Cancer
Cancer type
Reason: Memerlukan pemeriksaan
- Immunotherapy
Treatment category
Reason: Memerlukan pemeriksaan
- Targeted therapy
Treatment category
Reason: Memerlukan pemeriksaan
- PD-L1
Biomarker
Reason: Diperiksa melalui
- Breast Cancer
Cancer type
Reason: Memerlukan pemeriksaan
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.